[Situation of sultopride among present-day neuroleptics].
The authors report preliminary clinical investigations about sultopride, a new substituted benzamid, related to sulpiride. The drug was administered to thirty-nine hospitalized psychotic patients. A very powerful and constant efficacy of sultopride was observed in 11 manic and hypomanic typical syndroms: excitation was controlled between the first and third day, with oral doses of 1,200-1,800 mg. But thymical inversion was observed in 8 cases (3 light anxious states and 5 typical melancholic syndroms). Besides, interesting improvements were obtained in atypical excitation disorders, chronic hallucinatory delusions, acute oniric and confusional states, schizophrenia and chronic alcoholism. Side-effects were frequent: extrapyramidal syndroms, often requiring antiparkinsonian correctors, somnolence, asthenia, and above all (in 30 percent of cases) psychical side-effects, consisting in depressive and anxious modifications of mood, even apart from manic-melancholic psychosis. This psychotropic depressive effect appears as very interesting theoretically, and justifies further enquiry.
D001007:Anxiety; D001247:Asthenia / Q000139:chemically induced; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003702:Delusions / Q000188:drug therapy; D003863:Depression / Q000139:chemically induced; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D011604:Psychoses, Alcoholic / Q000188:drug therapy; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use
D001549:Benzamides; D014149:Tranquilizing Agents; D013469:Sulpiride
Essai de situation du sultopride parmi les neuroleptiques actuels